EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810

Leonard J Appleman iD, Se Eun Kim, Wayne B Harris, Sumanta K Pal iD, Michael R Pins, Jill Kolesar iD, Neeraj Agarwal iD, Rahul A Parikh iD, Daniel A Vaena iD, Christopher W Ryan, Mehmood Hashmi, Brian A Costello iD und 6 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01544 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Leonard J Appleman und 17 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, PA. Hauptthemen laut MEDLINE: Indazoles, Carcinoma, Renal Cell, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated analysis at 60.5-month median follow-up from random assignment (95% CI, 59.3 to 71.0) showed that the 3-year DFS was 27.4% (95% CI, 17.9 to 41.7) for pazopanib and 21.9% (95% CI, 13.3 to 36.2) for placebo. Hazard ratio (HR) for DFS was 0.90 ([95% CI, 0.60 to 1.34]; P one-sided = .29) in favor of pazopanib. Three-year overall survival (OS) was 81.9% (95% CI, 72.7 to 92.2) for pazopanib and 91.4% (95% CI, 84.4 to 98.9) for placebo. The HR for OS was 2.55 (95% CI, 1.23 to 5.27) in favor of placebo ( P two-sided = .012). Health-related quality-of-life measures deteriorated in the pazopanib group during the treatment period. CONCLUSION Pazopanib did not improve DFS as the primary end point compared with blinded placebo in patients with mRCC with NED after metastasectomy. In addition, there was a concerning trend favoring placebo in OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndazolesCarcinoma, Renal CellPyrimidinesSulfonamidesKidney NeoplasmsMetastasectomyHumansDouble-Blind MethodMaleFemaleMiddle AgedAgedAdultAngiogenesis InhibitorsDisease-Free SurvivalAged, 80 and over

Substanzen

IndazolespazopanibPyrimidinesSulfonamidesAngiogenesis Inhibitors

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center, Pittsburgh, PA.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Emory University and Atlanta VA Medical Center, Atlanta, GA.
  • City of Hope Comprehensive Cancer Center, Duarte, CA.
  • Rosalind Franklin University, Chicago, IL.
  • University of Kentucky, Lexington, KY.

ORCID-Profile: Leonard J Appleman, Sumanta K Pal, Jill Kolesar, Neeraj Agarwal, Rahul A Parikh, Daniel A Vaena, Brian A Costello, David Cella, Janice P Dutcher, Naomi B Haas, Lynne I Wagner

Förderung

  • NCI NIH HHS

Zitieren

APA

Appleman, L. J., Kim, S. E., Harris, W. B., Pal, S. K., Pins, M. R., Kolesar, J., Agarwal, N., Parikh, R. A., Vaena, D. A., Ryan, C. W., Hashmi, M., Costello, B. A., Cella, D., Dutcher, J. P., DiPaola, R. S., Haas, N. B., Wagner, L. I., & Carducci, M. A. (2024). Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01544

Vancouver

Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, et al. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01544

BibTeX
@article{Appleman2024,
  author = {Appleman, Leonard J and Kim, Se Eun and Harris, Wayne B and Pal, Sumanta K and Pins, Michael R and Kolesar, Jill and Agarwal, Neeraj and Parikh, Rahul A and Vaena, Daniel A and Ryan, Christopher W and Hashmi, Mehmood and Costello, Brian A and Cella, David and Dutcher, Janice P and DiPaola, Robert S and Haas, Naomi B and Wagner, Lynne I and Carducci, Michael A},
  title = {Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01544}
}
Kostenlos starten →